 Cyclacel Pharmaceuticals Inc NASDAQ: CYCC is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with. 